{"disease":{"id":"driver-mutation","name":"driver mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07062172","title":"Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":1753,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT05277844","title":"Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT06518018","title":"Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"The First People's Hospital of Neijiang","has_results":false},{"nct_id":"NCT06322095","title":"A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Suzhou Genhouse Bio Co., Ltd.","has_results":false},{"nct_id":"NCT05800340","title":"Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}